

PUBLIKATIONSLISTE
Prof. Dr. med. Manfred Hensel
Stand 24.3.09

1. Originalarbeiten mit Erst- oder Letztautorenschaft

Kornacker M, Kornacker B, Schmitt C, Leo E, Ho AD, **Hensel M**.
Commercial LightCycler-based quantitative real-time PCR compared to nested PCR for monitoring of Bcl-2/IgH rearrangement in patients with follicular lymphoma.
Ann Hematol. 2009 Jan;88(1):43-50. Epub 2008 Jul 18.

Hensel M, Zoz M, Ho AD.
Complementary and alternative medicine in patients with chronic lymphocytic leukemia.
Supp Care Cancer, 2008 May 6. [Epub ahead of print]

Schweizer C, Reu FJ, Ho AD, **Hensel M**.
Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab.
Ann Hematol. 2007 Oct;86(10):711-7. Epub 2007 Jul 11.

Krämer A, Reiter A, Kruth J, Erben P, Hochhaus A, Müller M, Cross NC, Jones AV, Ho AD, **Hensel M**.
JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia.
Lancet Oncol. 2007 Jul;8(7):658-60. No abstract available.

Hensel M, Dreger P, Ho AD.
IgM-Gammopathie: Differentialdiagnose, Klinik und Therapie.
Dtsch Arztebl 2007; 104(26): A-1907 / B-1684 / C-1620

Hensel M, Zoz M, Giesecke C, Benner A, Neben K, Jauch A, Stilgenbauer S, Ho AD, Krämer A.
High rate of centrosome aberrations and correlation with proliferative activity in patients with untreated B-cell chronic lymphocytic leukemia.
Int J Cancer. 2007 Sep 1;121(5):978-83.

Ho AD, **Hensel M**.
Pentostatin and purine analogs for indolent lymphoid malignancies.
Future Oncol. 2006 Apr;2(2):169-83. Review.

Ho AD, **Hensel M**.
Pentostatin for the treatment of indolent lymphoproliferative disorders.
Semin Hematol. 2006 Apr;43(2 Suppl 2):S2-10. Review.

Hensel M, Villalobos M, Kornacker M, Krasniqi F, Ho AD.
Pentostatin/cyclophosphamide with or without rituximab: an effective regimen for patients with Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma.
Clin Lymphoma Myeloma. 2005 Sep;6(2):131-5.

Hensel M, Buss EC, Tiemann M, Parwaresch R, Libicher M, Fruehauf S, Ho AD.
Secondary follicular lymphoma of the bone, transformed into large cell lymphoma, in a patient with chronic lymphocytic leukaemia: an uncommon manifestation of Richter's syndrome.

Eur J Haematol. 2004 Mar;72(3):217-21.

[Hensel M, Kornacker M, Yammeni S, Egerer G, Ho AD.](#)

Disease activity and pretreatment, rather than hypogammaglobulinaemia, are major risk factors for infectious complications in patients with chronic lymphocytic leukaemia.

Br J Haematol. 2003 Aug;122(4):600-6.

PMID: 12899715 [PubMed - indexed for

[Hensel M, Ho AD.](#)

Successful treatment of a patient with hairy cell leukemia and pentostatin-induced autoimmune thrombocytopenia with rituximab.

Am J Hematol. 2003 May;73(1):37-40.

[Hensel M, Ho AD, Bastert G, Schneeweiss A.](#)

Prognostic markers for survival after high-dose chemotherapy with autologous stem-cell transplantation for breast cancer.

Ann Oncol. 2003 Feb;14(2):341. No abstract available.

[Hensel M, Fiehn C, Ho AD.](#)

[Stem cell transplantation in primary systemic vasculitis]

Med Klin (Munich). 2003 Jan 15;98(1):13-8. Review. German.

[Hensel M, Schneeweiss A, Sinn HP, Egerer G, Solomayer E, Haas R, Bastert G, Ho AD.](#)

P53 is the strongest predictor of survival in high-risk primary breast cancer patients undergoing high-dose chemotherapy with autologous blood stem cell support.

Int J Cancer. 2002 Jul 20;100(3):290-6.

[Hensel M, Egerer G, Schneeweiss A, Goldschmidt H, Ho AD.](#)

Quality of life and rehabilitation in social and professional life after autologous stem cell transplantation.

Ann Oncol. 2002 Feb;13(2):209-17.

[Hensel M, Schneeweiss A, Sinn HP, Egerer G, Kornacker M, Solomayer E, Haas R, Bastert G, Ho AD.](#)

Stem cell dose and tumorbiologic parameters as prognostic markers for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous blood stem cell support.

Stem Cells. 2002;20(1):32-40.

[Schneeweiss A*, Hensel M*, Goerner R, Khbeis T, Hohaus S, Egerer G, Solomayer E, Haas R, Grischke EM, Bastert G, Ho AD.](#)

Comparison of double and triple high-dose chemotherapy with autologous blood stem cell transplantation in patients with metastatic breast cancer. (*shared first author)

Stem Cells. 2001;19(2):151-60.

[Hensel M, Breitbart A, Ho AD.](#)

Autologous hematopoietic stem-cell transplantation for Behçet's disease with pulmonary involvement.

N Engl J Med. 2001 Jan 4;344(1):69. No abstract available

2. Originalarbeiten mit Ko-Autorenschaft

Kornacker M, Stumm J, Pott C, Dietrich S, Süssmilch S, **Hensel M**, Nickelsen M, Witzens-Harig M, Kneba M, Schmitz N, Ho AD, Dreger P.
Characteristics of relapse after autologous stem-cell transplantation for follicular lymphoma: a long-term follow-up.
Ann Oncol. 2009 Jan 29. [Epub ahead of print]

Witzens-Harig M, Reiz M, Heiss C, Benner A, **Hensel M**, Neben K, Dreger P, Kraemer A, Ho AD.
Quality of life during maintenance therapy with the anti-CD20 antibody rituximab in patients with B cell non-Hodgkin's lymphoma: results of a prospective randomized controlled trial.
Ann Hematol. 2009 Jan;88(1):51-7. Epub 2008 Jul 30.

Zwick C, Birkmann J, Peter N, Bodenstein H, Fuchs R, Hänel M, Reiser M, **Hensel M**, Clemens M, Zeynalova S, Ziepert M, Pfreundschuh M; German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL).
Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP regimen (cisplatin, etoposide, mitoxantrone and prednisone).
Ann Hematol. 2008 Sep;87(9):717-26. Epub 2008 Jun 28.

[Haas J, Schopp L, Storch-Hagenlocher B, Fritzsching B, Jacobi C, Milkova L, Fritz B, Schwarz A, Suri-Payer E, **Hensel M**, Wildemann B.](#)
Specific recruitment of regulatory T cells into the CSF in lymphomatous and carcinomatous meningitis.
Blood. 2008 Jan 15;111(2):761-6. Epub 2007 Oct 29.

[Dreger P, Rieger M, Seyfarth B, **Hensel M**, Kneba M, Ho AD, Schmitz N, Pott C.](#)
Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome.
Haematologica. 2007 Jan;92(1):42-9.

[Witzens-Harig M, Heilmann C, **Hensel M**, Kornacker M, Benner A, Haas R, Fruehauf S, Ho AD.](#)
Long-term follow-up of patients with non-Hodgkin lymphoma following myeloablative therapy and autologous transplantation of CD34+-selected peripheral blood progenitor cells.
Stem Cells. 2007 Jan;25(1):228-35.

Mey UJ, Olivieri A, Orlopp KS, Rabe C, Strehl JW, Gorschlüter M, **Hensel M**, Flieger D, Glasmacher AG, Schmidt-Wolf IG. DHAP in combination with rituximab vs DHAP alone as salvage treatment for patients with relapsed or refractory diffuse large B-cell lymphoma: a matched-pair analysis. Leuk Lymphoma. 2006 Dec;47(12):2558-66.

[Mey UJ, Orlopp KS, Flieger D, Strehl JW, Ho AD, **Hensel M**, Bopp C, Gorschlüter M, Wilhelm M, Birkmann J, Kaiser U, Neubauer A, Florschütz A, Rabe C, Hahn C, Glasmacher AG, Schmidt-Wolf IG.](#)
Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.
Cancer Invest. 2006 Oct;24(6):593-600.

Schlenk RF, Frohling S, Hartmann F, Fischer JT, Glasmacher A, Del Valle F, Gotze K, Nerl C, Schoch R, Pralle H, Mergenthaler HG, **Hensel M**, Koller E, Kirchen H, Matzdorff A, Salwender H, Biedermann HG, Kremers S, Haase D, Benner A, Dohner K, Dohner H.
Intensive consolidation versus oral maintenance therapy in patients 61 years or older with

acute myeloid leukemia in first remission: results of second randomization of the AML HD98-B treatment Trial.
Leukemia. 2006 Apr;20(4):748-50.

[Kornacker M, Moldenhauer G, Herbst M, Weilguni E, Tita-Nwa F, Harter C, Hensel M, Ho AD.](#)

Cytokine-induced killer cells against autologous CLL: direct cytotoxic effects and induction of immune accessory molecules by interferon-gamma.
Int J Cancer. 2006 Sep 15;119(6):1377-82.

Eichhorst BF, Busch R, Hopfinger G, Pasold R, **Hensel M**, Steinbrecher C, Siehl S, Jaeger U, Bergmann M, Stilgenbauer S, Schweighofer C, Wendtner CM, Doehner H, Brittinger G, Emmerich B, Hallek M. Fludarabine plus cyclophosphamide versus fludarabine alone in first line therapy of younger patients with chronic lymphocytic leukemia.
Blood. 2006 Feb 1;107(3):885-91. Epub 2005 Oct 11.

[Schmitt C, Grundt A, Buchholtz C, Scheuer L, Benner A, Hensel M, Ho AD, Leo E.](#)

One single dose of rituximab added to a standard regimen of CHOP in primary treatment of follicular lymphoma appears to result in a high clearance rate from circulating bcl-2/IgH positive cells: Is the end of molecular monitoring near?
Leuk Res. 2006 Dec;30(12):1563-8. Epub 2006 Mar 10.

[Schmitt C, Balogh B, Grundt A, Buchholtz C, Leo A, Benner A, Hensel M, Ho AD, Leo E.](#)

The bcl-2/IgH rearrangement in a population of 204 healthy individuals: occurrence, age and gender distribution, breakpoints, and detection method validity.
Leuk Res. 2006 Jun;30(6):745-50. Epub 2005 Nov 16.

[Maurer B, Hensel M, Max R, Fiehn C, Ho AD, Lorenz HM.](#)

Autologous haematopoietic stem cell transplantation for Behcet's disease with pulmonary involvement: analysis after 5 years of follow up.
Ann Rheum Dis. 2006 Jan;65(1):127-9. Epub 2005 May 26.

[Nikendei C, Schilling T, Nawroth P, Hensel M, Ho AD, Schwenger V, Zeier M, Herzog W, Schellberg D, Katus HA, Dengler T, Stremmel W, Müller M, Jünger J.](#)

[Integrated skills laboratory concept for undergraduate training in internal medicine]
Dtsch Med Wochenschr. 2005 May 6;130(18):1133-8. German.

Schlenk RF, Germing U, Hartmann F, Glasmacher A, Fischer JT, Del Valle Y Fuentes F, Gotze K, Pralle H, Nerl C, Salwender H, Grimminger W, Petzer A, **Hensel M**, Benner A, Zick L, Dohner K, Frohling S, Dohner H. High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia.
Leukemia. 2005 Jun;19(6):978-83.

[Bochtler T, Hensel M, Lorenz HM, Ho AD, Mahlknecht U.](#)

Chronic lymphocytic leukaemia and concomitant relapsing polychondritis: a report on one treatment for the combined manifestation of two diseases.
Rheumatology (Oxford). 2005 Sep;44(9):1199. Epub 2005 Apr 26.

[Schneeweiss A, Diel I, Hensel M, Kaul S, Sinn HP, Unnebrink K, Rudlowski C, Lauschner I, Schuetz F, Egerer G, Haas R, Ho AD, Bastert G.](#)

Micrometastatic bone marrow cells at diagnosis have no impact on survival of primary breast cancer patients with extensive axillary lymph node involvement treated with stem cell-supported high-dose chemotherapy.
Ann Oncol. 2004 Nov;15(11):1627-32.

[Reusch U, Le Gall F, Hensel M, Moldenhauer G, Ho AD, Little M, Kipriyanov SM.](#)
Effect of tetravalent bispecific CD19xCD3 recombinant antibody construct and CD28 costimulation on lysis of malignant B cells from patients with chronic lymphocytic leukemia by autologous T cells.
Int J Cancer. 2004 Nov 10;112(3):509-18.

Mechtersheimer G, Egerer G, **Hensel M**, Rieker RJ, Libicher M, Lehnert T, Penzel R.
Gastrointestinal stromal tumours and their response to treatment with the tyrosine kinase inhibitor imatinib. Virchows Arch. 2004 Feb;444(2):108-18. Epub 2004 Jan 20. Review.

[Schetelig J, Thiede C, Bornhauser M, Schwerdtfeger R, Kiehl M, Beyer J, Sayer HG, Kroger N, Hensel M, Scheffold C, Held TK, Hoffken K, Ho AD, Kienast J, Neubauer A, Zander AR, Fauser AA, Ehninger G, Siegert W; Cooperative German Transplant Study Group.](#)
Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group.
J Clin Oncol. 2003 Jul 15;21(14):2747-53.

Schlenk RF, Benner A, Hartmann F, del Valle F, Weber C, Pralle H, Fischer JT, Gunzer U, Pezzutto A, Weber W, Grimminger W, Preiss J, **Hensel M**, Frohling S, Dohner K, Haas R, Dohner H; AML Study Group Ulm (AML SG ULM). Risk-adapted postremission therapy in acute myeloid leukemia: results of the German multicenter AML HD93 treatment trial.
Leukemia. 2003 Aug;17(8):1521-8.

[Schetelig J, Thiede C, Bornhäuser M, Schwerdtfeger R, Kiehl M, Beyer J, Kröger N, Hensel M, Scheffold C, Ho AD, Kienast J, Neubauer A, Zander AR, Fauser AA, Ehninger G, Siegert W.](#)
Reduced non-relapse mortality after reduced intensity conditioning in advanced chronic lymphocytic leukemia.
Ann Hematol. 2002;81 Suppl 2:S47-8.

Schulz H, Klein SK, Rehwald U, Reiser M, Hinke A, Knauf WU, Aulitzky WE, **Hensel M**, Herold M, Huhn D, Hallek M, Diehl V, Engert A; German CLL Study Group. Phase-II Study of a combined Immuno-Chemotherapy using Rituximab and Fludarabine in Patients With Chronic Lymphocytic Leukemia
Blood 2002 Nov 1;100(9):3115-20

[Egerer G, Goldschmidt H, Hensel M, Harter C, Schneeweiss A, Ehrhard I, Bastert G, Ho AD.](#)
Continuous infusion of ceftazidime for patients with breast cancer and multiple myeloma receiving high-dose chemotherapy and peripheral blood stem cell transplantation.
Bone Marrow Transplant. 2002 Oct;30(7):427-31.

[Schneeweiss A, Hensel M, Sinn P, Khbeis T, Haas R, Bastert G, Ho AD.](#)
Characteristics associated with long-term progression-free survival following high-dose chemotherapy in metastatic breast cancer and influence of chemotherapy dose.
Ann Oncol. 2002 May;13(5):679-88.

[Egerer G, Hensel M, Ho AD.](#)
Infectious complications in chronic lymphoid malignancy.
Curr Treat Options Oncol. 2001 Jun;2(3):237-44. Review.

[Schlenk RF, Hartmann F, Hensel M, Jung W, Weber-Nordt R, Gabler A, Haas R, Ho AD, Trümper L, Döhner H.](#)

Less intense conditioning with fludarabine, cyclophosphamide, idarubicin and etoposide (FCIE) followed by allogeneic unselected peripheral blood stem cell transplantation in elderly patients with leukemia.

Leukemia. 2002 Apr;16(4):581-6.

[Perz J, Topaly J, Fruehauf S, Hensel M, Ho AD.](#)

Level of CD 20-expression and efficacy of rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemia.

Leuk Lymphoma. 2002 Jan;43(1):149-51.

[Schneeweiss A, Goerner R, Hensel M, Lauschner I, Sinn P, Kaul S, Egerer G, Beldermann F, Geberth M, Solomayer E, Grischke EM, Haas R, Ho AD, Bastert G.](#)

Tandem high-dose chemotherapy in high-risk primary breast cancer: a multivariate analysis and a matched-pair comparison with standard-dose chemotherapy.

Biol Blood Marrow Transplant. 2001;7(6):332-42.

Buchbeiträge

Hensel M. Substitution von Immunglobulinen. In: *Supportivtherapie bei malignen Erkrankungen*. Herausgeber: Link; Bokemeyer, Feyer. Deutscher Ärzteverlag Köln, 2006

Hensel M. Einsatz monoklonaler Antikörper bei malignen Lymphomen (Rituximab, Zevalin/ Bexxar, Epratuzumab, HuMax-CD20, Galiximab). In: *Antikörpertherapie in der Hämatologie und Onkologie*. UNI-MED Verlag Bremen. 2007

Fiehn C, **Hensel M.** High Dose Chemotherapy with Haematopoietic Stem Cell Transplantation in Primary Systemic Vasculitis, Behcet's disease and Sjogren's Syndrome. *Stem Cell Therapy for Autoimmune Disease*. eds. Marmont and Burt; Landes Bioscience, Georgetown, USA. 2003